Vaxcyte (PCVX) Net Income towards Common Stockholders (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$322.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 113.95% year-over-year to -$322.9 million in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 160.47% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 60.03% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$322.9 million, up from -$378.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PCVX reached as high as $92.7 million in Q3 2023 and fell as low as -$623.7 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$188.6 million across 5 years, with a median of -$117.3 million in 2024.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 259.99% in 2023 and fell as far as 699.14% in 2023.
• Year by year, Net Income towards Common Stockholders stood at -$78.0 million in 2022, then tumbled by 699.14% to -$623.7 million in 2023, then jumped by 81.19% to -$117.3 million in 2024, then sank by 222.39% to -$378.2 million in 2025, then grew by 14.61% to -$322.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$322.9 million in Q1 2026, -$378.2 million in Q4 2025, and -$331.1 million in Q3 2025.